SEC Form 4 · accession 0001209191-17-030443
Viking Therapeutics, Inc. · VKTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Morneau
Officer — Chief Financial Officer
Period of report
May 4, 2017
Accepted (ET)
May 5, 2017 · 6:25 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001607678
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.00001 per shareF2 | May 4, 2017 | F | 8,192 | $1.34 | D | 80,604 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain shares of restricted stock.
- F2Includes 147 shares acquired on May 20, 2015 pursuant to the Issuer's 2014 Employee Stock Purchase Plan, 2,643 shares acquired on November 20, 2015 pursuant to the Issuer's 2014 Employee Stock Purchase Plan, 5,694 shares acquired on May 20, 2016 pursuant to the Issuer's 2014 Employee Stock Purchase Plan, and 2,908 shares acquired on November 18, 2016 pursuant to the Issuer's 2014 Employee Stock Purchase Plan.